A Phase 3 interventional study of Marizomib and Temozolomide in Newly Diagnosed Glioblastoma, sponsored by European Organisation for Research and Treatment of Cancer - EORTC. Completed at 82 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-01.
Sponsored by European Organisation for Research and Treatment of Cancer - EORTC · Phase 3, Interventional, and Treatment
Among 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC — 1 open to participants now, 1 under way, 1 of them phase 3. Glioblastoma · European Organisation for Research and Treatment of Cancer - EORTC.
Among the 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC, this one has the largest enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2018, is one of 5 in phase 3, and was the 17th registered.
2,132 studies on the registry are indexed under Glioblastoma; 464 are open to participants now.
Browse Glioblastoma studies →1 of the 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC is open now, in 11 countries. Recruiting first, the newest first:
European Organisation for Research and Treatment of Cancer - EORTC · Sites in Austria, Belgium, Czechia and 8 more countries
By country, each count listing its studies:
Of the 339 Glioblastoma studies recruiting now, 234 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 10 · Phase 3 5
First in 1999; this study’s year is marked. 2 started in 2018.
This study's enrollment of 749 is above the median of 36 across 1,753 interventional studies indexed under Glioblastoma.
Median enrollment 55 across the 18 interventional studies, 599 across the 1 observational. Of the 16 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
European Organisation for Research and Treatment of Cancer - EORTC is the lead sponsor of 352 studies on the registry; 23 are open to participants now.
1 of the studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
Among the 20 studies in Glioblastoma by European Organisation for Research and Treatment of Cancer - EORTC, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The standard of care for newly diagnosed glioblastoma includes surgery, involved-field radiotherapy, and concomitant and six cycles of maintenance temozolomide chemotherapy, however the prognosis remains dismal. Marizomib has been tested in patients with newly diagnosed and recurrent glioblastoma in phase I and phase II studies. In patients with recurrent glioblastoma, marizomib was administered as a single agent or in combination with bevacizumab (NCT02330562). Based on encouraging observations, a phase I/II trial of marizomib in combination with Temozolomide+Radiotherapy(TMZ/RT) followed by Temozolomide (TMZ) in newly diagnosed glioblastoma has been launched (NCT02903069) which explores safety and tolerability of this triple combination and which shall help to determine the dose for further clinical trials in glioblastoma. In this context, given that marizomib has been established as a safe addition to the standard TMZ/RT -->TMZ, a phase III study is considered essential to establishing its impact on overall survival.
Inclusion Criteria:
The patient shows adequate organ functions as assessed by the specified laboratory values within 2 weeks prior to randomization defined as adequate bone marrow, renal and hepatic function within the following ranges:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anaemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiotherapy + Temozolomide + Marizomib followed by adjuvant Temozolomide + Marizomib
Drug: Marizomib · Drug: Temozolomide · Radiation: radiotherapy
Radiotherapy + Temozolomide followed by adjuvant Temozolomide
Drug: Temozolomide · Radiation: radiotherapy
Intravenous administration of Marizomib
Oral Administration of Temozolomide
Also known as: TMZ
60 Gy in 30 fractions over 6 weeks
Also known as: RT
Overall Survival (OS)
Overall Survival (OS): OS is defined as the number of days from date of randomization to the date of death due to any cause. If a patient has not died, the data will be censored at the last date documented to be alive.
Time frame: From the date of randomization up to the date of death, assessed up to 49 months
Progression Free Survival (PFS)
PFS is defined as the number of days from date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology criteria (by investigator) or to the date of death due to any cause, if disease progression does not occur. Patients for whom neither death nor progression have been documented were censored on the date of the last radiological assessment that the patient was progression-free. If a patient with no post-baseline radiological assessment then the data were censored at the date of randomization. Patients with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where the patient was documented to be progression free. Patients who received new anti-cancer therapy or cancer-related surgery prior to progression or death were not censored at the last assessment where the patient was documented as progression free prior to the new therapy.
Time frame: From the date of randomization until the date of first objective progression or the date of patient's death whichever occurs first, assessed up to 49 months
Health-related Quality of Life (HRQol)
HRQoL was assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3. The primary HRQol score is Physical Functioning. It is reported at week 16 during the Temozolomide (TMZ) maintenance phase. Physical functioning score is ranging 0 to 100. A large scores indicate a good physical functioning. A negative difference indicates a worsening physical functioning.
Time frame: From randomization until progression or death which ever occurs first, reported at week 16 by the mean difference from baseline assessment.
Mini Mental State Examination (MMSE)
MMSE is a brief, standardized tool to grade patients' neurocognitive function. It is an 11-question measure that tests five areas of neurocognitive function: orientation, registration, attention and calculation, recall, and language. A large MMSE score indicates a good cognitive functioning. The maximum MMSE score is 30 which corresponds to the best neurocognitive function and minimum MMSE score is 0 the worst neurocognitive function.The patient's neurocognitive function are considered 'impaired' if MMSE is 26 or less and 'normal' if it is 27 or more. MMSE has been validated and extensively used in both clinical practice and research. It is reported at week 16 during the Temozolomide (TMZ) maintenance phase. A negative difference indicates a worsening cognitive functioning. Difference range reported in the data table is min -19 and max 10. The mean difference is reported with 95% confidence interval (CI). A CI which excludes 0 indicates a significant mean MMSE score change.
Time frame: From the date of randomization until end of treatment. It is reported at week 16 by the mean difference from baseline assessment.
Patient registration was accepted from authorized investigators. Patients were registered on the Electronic Data Capture system. To access it, the investigator needed a user name and a password which were provided by the EORTC Headquarters. In case of problems investigators could contact the EORTC Clinical Data Manager. A Subject Identifier was allocated to the patient. This number allowed the identification of the patient in the Electronic Data Capture.
| Milestone | Experimental Arm | Standard Arm |
|---|---|---|
| Started | 374 | 375 |
| Completed | 125 | 8 |
| Not completed | 249 | 367 |
| Withdrew: Lack of efficacy | 184 | 156 |
| Withdrew: Adverse event | 36 | 118 |
| Withdrew: Withdrawal by subject | 22 | 59 |
| Withdrew: Physician decision | 3 | 18 |
| Withdrew: Death | 2 | 4 |
| Withdrew: Other reasons | 2 | 11 |
| Withdrew: Protocol violation | 0 | 1 |
Overall Survival (OS): OS is defined as the number of days from date of randomization to the date of death due to any cause. If a patient has not died, the data will be censored at the last date documented to be alive.
| Months | Experimental Arm | Standard Arm |
|---|---|---|
| Overall Survival (OS) | 16.13 (14.92 to 17.77) | 15.08 (13.73 to 16.99) |
PFS is defined as the number of days from date of randomization to the date of earliest disease progression based on Response Assessment in Neuro-Oncology criteria (by investigator) or to the date of death due to any cause, if disease progression does not occur. Patients for whom neither death nor progression have been documented were censored on the date of the last radiological assessment that the patient was progression-free. If a patient with no post-baseline radiological assessment then the data were censored at the date of randomization. Patients with two or more missing response assessments prior to a visit with documented disease progression (or death) were censored at the last visit where the patient was documented to be progression free. Patients who received new anti-cancer therapy or cancer-related surgery prior to progression or death were not censored at the last assessment where the patient was documented as progression free prior to the new therapy.
| Months | Experimental Arm | Standard Arm |
|---|---|---|
| Progression Free Survival (PFS) | 6.34 (5.82 to 7.85) | 6.11 (4.93 to 7.29) |
HRQoL was assessed with the EORTC Quality of Life Questionnaire (QLQ-C30) version 3. The primary HRQol score is Physical Functioning. It is reported at week 16 during the Temozolomide (TMZ) maintenance phase. Physical functioning score is ranging 0 to 100. A large scores indicate a good physical functioning. A negative difference indicates a worsening physical functioning.
| score on a scale | Experimental Arm | Standard Arm |
|---|---|---|
| Health-related Quality of Life (HRQol) | -11.8 (-15.0 to -8.7) | -5.4 (-8.0 to -2.9) |
MMSE is a brief, standardized tool to grade patients' neurocognitive function. It is an 11-question measure that tests five areas of neurocognitive function: orientation, registration, attention and calculation, recall, and language. A large MMSE score indicates a good cognitive functioning. The maximum MMSE score is 30 which corresponds to the best neurocognitive function and minimum MMSE score is 0 the worst neurocognitive function.The patient's neurocognitive function are considered 'impaired' if MMSE is 26 or less and 'normal' if it is 27 or more. MMSE has been validated and extensively used in both clinical practice and research. It is reported at week 16 during the Temozolomide (TMZ) maintenance phase. A negative difference indicates a worsening cognitive functioning. Difference range reported in the data table is min -19 and max 10. The mean difference is reported with 95% confidence interval (CI). A CI which excludes 0 indicates a significant mean MMSE score change.
| score on a scale | Experimental Arm | Standard Arm |
|---|---|---|
| Mini Mental State Examination (MMSE) | -0.95 (-1.51 to -0.38) | -0.39 (-0.82 to 0.04) |
Collected over Adverse Events (AEs) were collected from first dose of radiotherapy up to 49 months after patient enrolment in the study. All-Cause Mortality was assessed through study completion, up to 49 months after patient enrolment in the study.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Arm | 55/309 (17.8%) | 114/305 (37.4%) | 300/305 (98.4%) |
| Standard Arm | 57/307 (18.6%) | 80/297 (26.9%) | 283/297 (95.3%) |
| Event | Experimental Arm | Standard Arm |
|---|---|---|
| SeizureNervous system disorders | 15/305 | 14/297 |
| Brain OedemaNervous system disorders | 8/305 | 8/297 |
| Malignant Neoplasm ProgressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 8/305 | 5/297 |
| Platelet Count DecreasedInvestigations | 2/305 | 7/297 |
| ThrombocytopeniaBlood and lymphatic system disorders | 7/305 | 1/297 |
| NauseaGastrointestinal disorders | 7/305 | 1/297 |
| Confusional StatePsychiatric disorders | 7/305 | 3/297 |
| HallucinationPsychiatric disorders | 7/305 | 0/297 |
| HeadacheNervous system disorders | 6/305 | 2/297 |
| General Physical Health DeteriorationGeneral disorders | 4/305 | 5/297 |
| Event | Experimental Arm | Standard Arm |
|---|---|---|
| NauseaGastrointestinal disorders | 205/305 | 122/297 |
| FatigueGeneral disorders | 188/305 | 170/297 |
| HeadacheNervous system disorders | 163/305 | 92/297 |
| VomitingGastrointestinal disorders | 158/305 | 53/297 |
| ConstipationGastrointestinal disorders | 126/305 | 97/297 |
| HallucinationPsychiatric disorders | 115/305 | 1/297 |
| AlopeciaSkin and subcutaneous tissue disorders | 73/305 | 99/297 |
| InsomniaPsychiatric disorders | 87/305 | 36/297 |
| Gait DisturbanceGeneral disorders | 72/305 | 15/297 |
| DizzinessNervous system disorders | 71/305 | 31/297 |
| Age, Categorical(Participants) | Experimental Arm | Standard Arm | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 287 | 276 | 563 |
| >=65 years | 87 | 99 | 186 |
| Age, Continuous(years) | Experimental Arm | Standard Arm | Total |
|---|---|---|---|
| Median | 58.5 (21 to 79) | 58.0 (20 to 79) | 58.0 (20 to 79) |
| Sex: Female, Male(Participants) | Experimental Arm | Standard Arm | Total |
|---|---|---|---|
| Female | 119 | 142 | 261 |
| Male | 255 | 233 | 488 |
| Race (NIH/OMB)(Participants) | Experimental Arm | Standard Arm | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 7 | 5 | 12 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 1 |
| Black or African American | 2 | 0 | 2 |
| White | 279 | 290 | 569 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 85 | 79 | 164 |
| Region of Enrollment(participants) | Experimental Arm | Standard Arm | Total |
|---|---|---|---|
| Canada | 104 | 108 | 212 |
| Austria | 6 | 7 | 13 |
| Netherlands | 45 | 44 | 89 |
| Belgium | 30 | 32 | 62 |
| United States | 21 | 19 | 40 |
| Norway | 4 | 4 | 8 |
| Denmark | 9 | 10 | 19 |
| United Kingdom | 8 | 7 | 15 |
| France | 55 | 54 | 109 |
| Switzerland | 20 | 24 | 44 |
| Germany | 38 | 37 | 75 |
| Spain | 34 | 29 | 63 |
| Karnofsky Performance Status(Participants) | Experimental Arm | Standard Arm | Total |
|---|---|---|---|
| 70/80 | 126 | 123 | 249 |
| 90/100 | 248 | 252 | 500 |
| Extent of surgery(Participants) | Experimental Arm | Standard Arm | Total |
|---|---|---|---|
| Gross total | 192 | 192 | 384 |
| Partial/biopsy | 182 | 183 | 365 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2018 to primary completion in Aug 2022, 48 months.
Results were first posted in Jan 2024, 1 year 5 months after primary completion.
Of 43 phase 3 interventional studies under Glioblastoma, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 44 and three quarters within 87. This study's 48 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Marizomib
European Organisation for Research and Treatment of Cancer - EORTC →